Health Plans Are Being Pushed to Prove Prevention Works
Dr. Alice Chen, Centene’s chief health officer, used this episode to make a point that health plans can no longer afford to treat prevention as a broad aspiration. The financial pressure on managed care organizations is too high, the burden of chronic disease is too heavy, and the margin for unproven programming is too thin. Evidence-based prevention, in this framing, is not a branding exercise. It is a way to decide which interventions deserve investment, which should be refined, and which should be stopped before they absorb scarce resources without changing patient outcomes.
The logic is straightforward, but the operational challenge is not. Health plans serve large, heterogeneous populations, and the same intervention can look helpful in one setting and ineffective in another. A screening program, nutrition referral, or community-based support service may appear attractive on paper, yet still fail if it is not directed at the right population, measured against the right outcomes, or designed to fit real-world barriers such as transportation, food insecurity, or competing social needs. Chen’s message centers on discipline: prevention programs should be evaluated with the same seriousness applied to drug coverage decisions or utilization management policies.
Food as Medicine Needs More Than Enthusiasm
The discussion on food as medicine initiatives sits at the center of that philosophy. Nutrition intervention has become one of the most visible areas in prevention strategy because diet influences cardiometabolic risk, diabetes control, and many downstream utilization patterns. Still, enthusiasm alone does not establish value. Food-based services must be supported by rigorous data before they are expanded broadly, especially when they are delivered through payer systems that must justify every dollar spent.
A nutrition program can fail in several ways. It may reach patients who are already relatively well connected to care while missing those with the highest unmet needs. It may improve satisfaction without moving outcomes that matter to clinicians and finance teams. It may help in the short term but prove too costly or too difficult to sustain at scale. The most responsible use of evidence-based prevention is to separate those possibilities early, before a pilot becomes a permanent line item.
This is where population health strategy intersects with clinical realism. Chronic disease does not respond to abstract goodwill; it responds to interventions that actually change behaviors, access, adherence, and daily living conditions. When food insecurity and poor diet are part of the pathway to disease progression, then nutrition support may have a logical role. But the intervention must be specific enough to measure and selective enough to target the people most likely to benefit.
Underserved Populations Require Tailored Design
Chen also emphasized that prevention cannot be designed as if every patient starts from the same place. Underserved populations often face structural barriers that blunt the impact of otherwise sensible interventions. A program built around frequent visits, digital engagement, or self-directed behavior change may be ineffective if participants cannot reliably access those resources. In that setting, the issue is not patient motivation alone; it is the fit between the intervention and the lived reality of the population.
Evidence-based prevention becomes especially important here because broad claims can obscure inequity. A program that succeeds in a commercially insured group may not transfer to Medicaid populations, rural communities, or patients managing multiple social and medical needs at once. Tailoring matters because risk is distributed unevenly, and the same barrier rarely presents in the same way across communities. Programs that ignore those differences can widen gaps while appearing efficient on a spreadsheet.
One sentence captures the bedside implication: prevention only works when the patient can actually use it.
Health plans therefore need more than enthusiasm for innovation. They need implementation models that reflect language access, cultural context, geographic access, and the intensity of support required to move a patient from enrollment to sustained engagement. Without that specificity, prevention programs can become well-intended noise.
Prevention Has to Compete With Waste
Chen’s comments also frame prevention as a cost-control strategy, but not in the blunt sense of simply spending less. The deeper aim is to reduce waste by steering resources toward interventions that change the trajectory of disease. Waste includes programs that are popular yet ineffective, duplicative services that do not alter outcomes, and scalable efforts launched before the evidence is mature enough to support expansion.
That standard is especially relevant in managed care, where every added benefit competes with other priorities. A plan cannot fund every promising idea indefinitely. It has to decide whether an intervention changes utilization, improves outcomes, and is strong enough to justify broader adoption. This is where prevention and accountability overlap. If a service reduces emergency visits, avoids avoidable complications, or helps patients stay stable in the community, it may earn its place. If it fails to demonstrate that kind of value, the program should be redesigned or retired.
The same principle applies to public-facing narratives about prevention. Nutrition support, chronic disease outreach, and community-based services often generate optimism because they align with what clinicians know about disease biology and social drivers of health. Yet health care systems and plans operate under finite budgets. Clinical plausibility is useful, but it is not the same thing as proof.
Data Should Decide What Scales Next
The strongest thread in the conversation is restraint. Prevention strategies should be tested, measured, and refined before they are widely deployed. Programs aimed at food insecurity or chronic disease prevention can be powerful, but only when they are built around evidence and adapted for the patients most likely to be left behind by standard models of care.
That approach reflects a broader shift in health care finance and delivery: prevention is moving from a moral claim to an operational one. Health plans that can demonstrate results will have a stronger case for investment, while those that rely on assumptions will struggle to defend their spending. Chen’s framework does not promise easy answers, and it does not pretend that every prevention idea deserves equal support. It asks for a tougher standard — one based on data, population fit, and measurable clinical impact.
For health plans, the next question is not whether prevention sounds worthwhile. It is which interventions can prove they improve outcomes enough to justify scaling, and which should stay confined to the pilot stage until the evidence is stronger.